<th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.
TDP-43 is a 414 amino acid protein with an N-terminal domain involved in RNA/DNA binding, a central glycine-rich domain for protein-protein interactions, and a C-terminal prion-like domain prone to aggregation. Key structural features include:
- N-terminal domain (1-102 aa): Mediates RNA/DNA binding and nuclear localization
- RNA recognition motif (RRM) 1 (106-176 aa): Binds UG-rich RNA sequences
- RRM2 (191-259 aa): Additional RNA-binding capacity
- Glycine-rich domain (274-306 aa): Protein interaction interface
- C-terminal prion domain (314-414 aa): Involved in aggregation and stress granule formation
TDP-43 is a DNA/RNA-binding protein involved in:
- Regulation of alternative splicing
- mRNA stability and transport
- Transcription regulation
- Formation of stress granules
- Regulation of non-coding RNA processing
- Neuronal RNA metabolism
In the healthy brain, TDP-43 is predominantly nuclear but can shuttle between nucleus and cytoplasm.
TDP-43 pathology is the hallmark of ALS and most cases of frontotemporal dementia (FTD):
- ALS/FTD: TDP-43 forms cytoplasmic inclusions in motor neurons and frontal cortex neurons
- ALS: >95% of ALS cases show TDP-43 pathology
- FTD: ~45% of FTD cases show TDP-43 pathology (FTLD-TDP)
- Mechanisms: Loss of nuclear function, gain of toxic aggregation, impaired RNA metabolism
Mutations in TARDBP cause familial ALS and FTD, confirming TDP-43 dysfunction as a disease driver.
- Antisense oligonucleotides: Targeting TARDBP mRNA to reduce mutant protein
- Small molecule inhibitors: Blocking aggregation or promoting clearance
- Gene therapy: Delivering wild-type TDP-43 or modulating expression
- Autophagy enhancers: Promoting clearance of TDP-43 aggregates
The study of Tdp 43 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
-
- 1 Neumann M, et al. (2006). Ubiquitinated TDP-43 in frontotemporal dementia and amyotrophic lateral sclerosis. Science. PMID:16400152.
- 2 Lagier-Tourenne C, et al. (2009). Rethinking ALS: The role of RNA processing. Cell. PMID:19853568.
- 3 Arai T, et al. (2006). TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun. PMID:16530386.
- 4 Rascovsky M, et al. (2011). Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. PMID:21753790.
- 5 Chen-Plotkin AS, et al. (2010). TDP-43 in neurodegenerative disorders. Nat Rev Neurol. PMID:20200514.
-